Review of quercetin in metabolic diseases shows promise but lacks clinical validation.

This review assesses the potential of quercetin as an intervention for a broad spectrum of metabolic conditions, including diabetes mellitus, metabolic dysfunction-associated fatty liver disease, obesity, atherosclerosis, hyperuricemia, gouty arthritis, hyperlipidemia, osteoporosis, and polycystic ovary syndrome. The study population, sample size, and specific setting are not reported in the available data. The analysis focuses on existing literature rather than a new primary study cohort.

Quercetin exhibits reported pharmacological activities characterized by anti-inflammatory, antioxidant, antiapoptotic, hypolipidemic, and hypoglycemic effects. Additionally, the use of nanodelivery systems is noted to enhance bioavailability, stability, and overall efficacy while mitigating dose-dependent toxicity. However, no absolute numbers, effect sizes, or p-values are provided for these outcomes as the input data does not contain specific quantitative results from clinical trials.

Safety and tolerability are described as favorable in humans, with no reported adverse events, serious adverse events, or discontinuations in the reviewed literature. Despite these positive safety signals, the review highlights significant limitations, including a lack of mechanistic depth, insufficient data on bioavailability enhancement, and a scarcity of clinical validation. The absence of clinical studies validating therapeutic efficacy remains a critical gap in the current evidence base.

The practice relevance indicates that quercetin shows considerable promise in the intervention of metabolic diseases. However, given the lack of clinical validation and the scarcity of studies confirming therapeutic efficacy, clinicians should interpret these findings with caution. The evidence is currently too weak to recommend quercetin as a standard treatment, and further high-quality clinical trials are needed before it can be integrated into routine practice.